{"classes":[{"categories":[{"measurements":[{"comment":"Median OS has not been reached for Cohort A and B due to fewer number of participants with events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median OS has not been reached for Cohort A and B due to fewer number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Upper limit of 95% confidence interval was not estimable due to fewer number of participants with events.","groupId":"OG002","lowerLimit":"969.0","upperLimit":"NA","value":"1689.0"},{"groupId":"OG003","lowerLimit":"281.0","upperLimit":"2143.0","value":"1847.0"},{"groupId":"OG004","lowerLimit":"119.0","upperLimit":"379.0","value":"209.0"},{"groupId":"OG005","lowerLimit":"150.0","upperLimit":"279.0","value":"200.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"65"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"48"},{"groupId":"OG005","value":"46"}],"units":"Participants"}],"description":"OS is defined as the interval from the first dose of study treatment until death, censored at the last date at which participant was known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"CP-CML participants R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG000","title":"Cohort A: CP-CML R-I"},{"description":"CP-CML participants who had T315I mutation of breakpoint cluster region-Abelson complex (BCR-ABL) were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG001","title":"Cohort B: CP-CML With T315I Mutation"},{"description":"AP-CML R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG002","title":"Cohort C: AP-CML R-I"},{"description":"AP-CML participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG003","title":"Cohort D: AP-CML With T315I Mutation"},{"description":"BP-CML or Ph+ ALL R-I to dasatinib or nilotinib or Ph+ ALL R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG004","title":"Cohort E: BP-CML/Ph+ ALL R-I"},{"description":"BP-CML or Ph+ ALL participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG005","title":"Cohort F: BP-CML or Ph+ ALL With T315I Mutation"}],"paramType":"MEDIAN","populationDescription":"Treated population included all participants assigned to Cohorts A to F who received at least 1 dose of ponatinib.","reportingStatus":"POSTED","timeFrame":"From the first dose of study treatment until death (Up to 96 months post last dose)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"days"}